Tourmaline Bio

Biotech & Life Sciences · New York City, United States · Founded 2022 · IPO 2023

Tourmaline Bio is a biotechnology company focused on developing transformative medicines aimed at dramatically improving the lives of patients with life-altering immune diseases. The company operates in the biopharmaceutical market, targeting rare and significant unmet medical needs. Tourmaline Bio serves patients suffering from severe immune disorders, working closely with healthcare providers and research institutions. Their business model revolves around the research, development, and commercialization of innovative therapies. Revenue is generated through the successful development and approval of these therapies, followed by their commercialization either directly or through partnerships with larger pharmaceutical companies. Keywords: biotechnology, immune diseases, transformative medicines, rare diseases, drug development, biopharmaceutical, healthcare, innovation, commercialization, research.

Valuation $991M

Total funding $100–500M

Power Law Unicorn$1–10B valuation tier

Featured in

Market map Rare Disease Therapeutics & Technologies Landscape

Investors

16 investors on Tourmaline Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage

QVT Financial LP

Hydra Ventures

Petrichor

Series A 3 investors entered at this stage

TCGX

Deep Track Capital

Cowen Healthcare Investments

Series B+ 10 investors entered at this stage

Paradigm BioCapital

RA Capital Management

Great Point Partners

Acuta Capital Partners

Qiming Venture Partners USA

Braidwell

Affinity Asset Advisors

StemPoint Capital

KVP Capital

Vivo Capital

Global footprint

Where Tourmaline Bio has talent and traffic

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

2.7K monthly visits
across markets

🇺🇸 United States74.1%

🇮🇳 India25.9%

Top 2 markets shown

Talent graph

The shape of Tourmaline Bio's talent

Dealroom maps Tourmaline Bio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

5 team members profilednamed & role-tagged by Dealroom

54 employeestotal headcount

1 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Tourmaline Bio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$3M patent portfolio · 6 active families

Estimated portfolio value

$3M

0.31% of market cap · 15.9× smaller than top peer Camurus ($49M)

6 active patent families

Where Tourmaline Bio innovates Active agentAntibody fragmentsAntiendomysial antibodiesCellEndocrinology

Where Tourmaline Bio concentrates vs peers

Each axis is a top-10 topic across Tourmaline Bio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Tourmaline Bio

An AI-synthesized read of the highest-engagement posts about Tourmaline Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tourmaline Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles